by Monoclonal antibodies are monoclonal antibodies that are made by identical immune cells that are all clones of a unique parent cell. They can have monovalent affinity, binding to the same epitope on antigens.
The Global Monoclonal Antibody Therapeutics Market is estimated to be valued at US$ 83.63 Bn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period from 2024 to 2031.
Key Takeaways
Key players operating in the Monoclonal Antibody Therapeutics are IOI Loders Croklaan, Ghana Nuts Company Ltd., and The Savannah Fruits Company. Key players related content comprises key players related content IOI Loders Croklaan, Ghana Nuts Company Ltd., and The Savannah Fruits Company are some of the prominent players operating in the monoclonal antibody therapeutics market.
Growing demand in the market: The Monoclonal Antibody Therapeutics Market Size is witnessing high growth due to the increasing demand for targeted therapies and rise in prevalence of chronic diseases and cancer. Monoclonal antibodies have revolutionized targeted cancer therapeutics. They are now being used to treat various types of cancers including breast cancer, lung cancer, and blood cancer.
Global expansion of market: The market is expanding globally driven by investments in research and development of novel antibody therapies. Companies are focusing on emerging markets for further expansion opportunities attributed to increasing healthcare expenditure. Several clinical trials are being conducted to evaluate the efficacy of monoclonal antibodies in treating new disease indications.
Market Key Trends
Continuous innovation is a key trend being observed in the monoclonal antibody therapeutics market. Vendors are focusing on developing advanced antibody therapies with increased efficacy and targeted delivery. Various monoclonal antibodies in clinical development have potential to dramatically change standard of care in their respective disease indications. Companies are investing heavily in development of antibody drug conjugates (ADCs), bispecific antibodies, and other engineered antibody formats with improved functionality. This is expected to open new avenues of growth for monoclonal antibody therapeutics over the forecast period.
Porter’s Analysis
Threat of new entrants: High capital requirements to develop MAbs and enter clinical trials act as a barrier. Bargaining power of buyers: Large pharmaceutical companies have higher bargaining power against MAbs manufacturers due to their consolidating nature. Bargaining power of suppliers: Monoclonal antibody suppliers have low bargaining power due to availability of substitutes and dispersing nature. Threat of new substitutes: Continuous development of novel therapies pose threat as substitutes to MAbs. Intense competition.
Geographical Regions
North America currently holds the highest share in the monoclonal antibody therapeutics market in terms of value due to developed healthcare infrastructure and high adoption of high-cost biologics and bio-similar drugs in the region. Asia Pacific is expected to witness the fastest growth during the forecast period owing to rising awareness about immunotherapy, increasing healthcare expenditure, and presence of less stringent regulations for drug approval.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
About Author - Ravina Pandya
Ravina Pandya,a content writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemicals and materials, etc. With an MBA in E-commerce, she has expertise in SEO-optimized content that resonates with industry professionals. LinkedIn Profile
